Medpace (MEDP) Set to Post Quarterly Earnings on Wednesday

Medpace (NASDAQ:MEDP) is expected to be announcing its Q3 2026 results after the market closes on Wednesday, October 21st. Analysts expect Medpace to post earnings of $4.44 per share and revenue of $714.47 million for the quarter. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 22, 2026 at 9:00 AM ET.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.10 earnings per share. On average, analysts expect Medpace to post $17.54 EPS for the current fiscal year and $19.17 EPS for the next fiscal year.

Medpace Stock Up 0.2%

Shares of NASDAQ MEDP opened at $619.66 on Tuesday. The business’s 50 day moving average price is $606.76 and its 200 day moving average price is $533.55. The firm has a market cap of $17.29 billion, a P/E ratio of 36.25, a P/E/G ratio of 2.76 and a beta of 1.18. Medpace has a 52 week low of $373.00 and a 52 week high of $677.90.

Insider Buying and Selling at Medpace

In related news, CEO August Troendle sold 49,018 shares of the business’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total value of $30,788,695.98. Following the completion of the transaction, the chief executive officer directly owned 433,372 shares in the company, valued at $272,205,286.92. The trade was a 10.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 336,140 shares of company stock worth $208,008,328. 20.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on MEDP. Truist Financial raised their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Barclays increased their price objective on shares of Medpace from $600.00 to $625.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. Jefferies Financial Group reiterated a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Finally, UBS Group initiated coverage on shares of Medpace in a report on Wednesday, September 30th. They set a “neutral” rating and a $673.00 target price for the company. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, Medpace currently has an average rating of “Hold” and an average target price of $607.73.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.